The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
TRKing Down an Old Oncogene in a New Era of Targeted Therapy
Open accessAbstract
The use of high-throughput next-generation sequencing techniques in multiple tumor types during the last few years has identified NTRK1, 2, and 3 gene rearrangements encoding novel oncogenic fusions in 19 different tumor types to date. These recent developments have led us to revisit an old oncogene, Trk (originally identified as OncD), which encodes the TPM3–NTRK1 gene fusion and was one of the first transforming chromosomal rearrangements identified 32 years ago. However, no drug has yet been approved by the FDA for cancers harboring this oncogene. This review will discuss the biology of the TRK family of receptors, their role in human cancer, the types of oncogenic alterations, and drugs that are currently in development for this family of oncogene targets. Significance: Precision oncology approaches have accelerated recently due to advancements in our ability to detect oncogenic mutations in tumor samples. Oncogenic alterations, most commonly gene fusions, have now been detected for the genes encoding the TRKA, TRKB, and TRKC receptor tyrosine kinases across multiple tumor types. The scientific rationale for the targeting of the TRK oncogene family will be discussed here. Cancer Discov; 5(1); 25–34. ©2014 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381
Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.11.025 · Cited by 2,317
Neurotrophins and their receptors: A convergence point for many signalling pathways
Chao, M. V. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1078 · Cited by 2,298
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964
Self-citationPhosphatidylinositol-3-OH kinase direct target of Ras
Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., & Downward, J. (1994) · Nature · doi:10.1038/370527a0 · Cited by 1,954
The trk proto-oncogene encodes a receptor for nerve growth factor
Klein, R., Jing, S., Nanduri, V., O'Rourke, E., & Barbacid, M. (1991) · Cell · doi:10.1016/0092-8674(91)90419-y · Cited by 1,401
The impact of translocations and gene fusions on cancer causation
Mitelman, F., Johansson, B., & Mertens, F. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2091 · Cited by 1,400
A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia
Klein, A. D., Kessel, A. G. V., Grosveld, G., Bartram, C. R., Hagemeijer, A., Bootsma, D., Spurr, N. K., Heisterkamp, N., Groffen, J., & Stephenson, J. R. (1982) · Nature · doi:10.1038/300765a0 · Cited by 1,378
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
Roberts, K. G., Li, Y., Payne-Turner, D., Harvey, R. C., Yang, Y.-L., Pei, D., McCastlain, K., Ding, L., Lu, C., Song, G., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403088 · Cited by 1,377
RET, ROS1 and ALK fusions in lung cancer
Takeuchi, K., Soda, M., Togashi, Y., Suzuki, R., Sakata, S., Hatano, S., Asaka, R., Hamanaka, W., Ninomiya, H., Uehara, H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2658 · Cited by 1,320
New driver mutations in non-small-cell lung cancer
Pao, W., & Girard, N. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70087-5 · Cited by 1,128
the St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project (2014) · Nature Genetics · doi:10.1038/ng.2938 · Cited by 1,105
Kaplan, D. R., Martin-Zanca, D., & Parada, L. F. (1991) · Nature · doi:10.1038/350158a0 · Cited by 1,055
Severe sensory and sympathetic neuropathies in mice carrying a disrupted Trk/NGF receptor gene
Smeyne, R. J., Klein, R., Schnapp, A., Long, L. K., Bryant, S., Lewin, A., Lira, S. A., & Barbacid, M. (1994) · Nature · doi:10.1038/368246a0 · Cited by 981
The landscape of kinase fusions in cancer
Stransky, N., Cerami, E., Schalm, S., Kim, J. L., & Lengauer, C. (2014) · Nature Communications · doi:10.1038/ncomms5846 · Cited by 968
Anchored multiplex PCR for targeted next-generation sequencing
Zheng, Z., Liebers, M., Zhelyazkova, B., Cao, Y., Panditi, D., Lynch, K. D., Chen, J., Robinson, H. E., Shim, H. S., Chmielecki, J., et al. (2014) · Nature Medicine · doi:10.1038/nm.3729 · Cited by 915
Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma
Tognon, C., Knezevich, S. R., Huntsman, D., Roskelley, C. D., Melnyk, N., Mathers, J. A., Becker, L., Carneiro, F., MacPherson, N., Horsman, D., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00180-0 · Cited by 911
Complex landscapes of somatic rearrangement in human breast cancer genomes
Stephens, P. J., McBride, D. J., Lin, M.-L., Varela, I., Pleasance, E. D., Simpson, J. T., Stebbings, L. A., Leroy, C., Edkins, S., Mudie, L. J., et al. (2009) · Nature · doi:10.1038/nature08645 · Cited by 845
New driver mutations in non-small-cell lung cancer
Tanoue, L. T. (2012) · Yearbook of Pulmonary Disease · doi:10.1016/j.ypdi.2012.01.036 · Cited by 831
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma
the International Cancer Genome Consortium PedBrain Tumor Project, Jones, D. T. W., Hutter, B., Jäger, N., Korshunov, A., Kool, M., Warnatz, H.-J., Zichner, T., Lambert, S. R., Ryzhova, M., et al. (2013) · Nature Genetics · doi:10.1038/ng.2682 · Cited by 825
A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences
Martin-Zanca, D., Hughes, S. H., & Barbacid, M. (1986) · Nature · doi:10.1038/319743a0 · Cited by 803
A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma
Knezevich, S. R., McFadden, D. E., Tao, W., Lim, J. F., & Sorensen, P. H. B. (1998) · Nature Genetics · doi:10.1038/ng0298-184 · Cited by 800
Klein, R., Smeyne, R. J., Wurst, W., Long, L. K., Auerbach, B. A., Joyner, A. L., & Barbacid, M. (1993) · Cell · doi:10.1016/0092-8674(93)90683-h · Cited by 699
Nakagawara, A., Arima-Nakagawara, M., Scavarda, N. J., Azar, C. G., Cantor, A. B., & Brodeur, G. M. (1993) · New England Journal of Medicine · doi:10.1056/nejm199303253281205 · Cited by 694
Neurotrophin receptors: A window into neuronal differentiation
Chao, M. V. (1992) · Neuron · doi:10.1016/0896-6273(92)90023-7 · Cited by 692
Kinase fusions are frequent in Spitz tumours and spitzoid melanomas
Wiesner, T., He, J., Yelensky, R., Esteve-Puig, R., Botton, T., Yeh, I., Lipson, D., Otto, G., Brennan, K., Murali, R., et al. (2014) · Nature Communications · doi:10.1038/ncomms4116 · Cited by 649
Indo, Y., Tsuruta, M., Hayashida, Y., Karim, M. A., Ohta, K., Kawano, T., Mitsubuchi, H., Tonoki, H., Awaya, Y., & Matsuda, I. (1996) · Nature Genetics · doi:10.1038/ng0896-485 · Cited by 646
Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer
Vaishnavi, A., Capelletti, M., Le, A. T., Kako, S., Butaney, M., Ercan, D., Mahale, S., Davies, K. D., Aisner, D. L., Pilling, A. B., et al. (2013) · Nature Medicine · doi:10.1038/nm.3352 · Cited by 607
Self-citationSuppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB
Douma, S., van Laar, T., Zevenhoven, J., Meuwissen, R., van Garderen, E., & Peeper, D. S. (2004) · Nature · doi:10.1038/nature02765 · Cited by 607
Stephens, R. M., Loeb, D. M., Copeland, T. D., Pawson, T., Greene, L. A., & Kaplan, D. R. (1994) · Neuron · doi:10.1016/0896-6273(94)90223-2 · Cited by 541
The integrated landscape of driver genomic alterations in glioblastoma
Frattini, V., Trifonov, V., Chan, J. M., Castano, A., Lia, M., Abate, F., Keir, S. T., Ji, A. X., Zoppoli, P., Niola, F., et al. (2013) · Nature Genetics · doi:10.1038/ng.2734 · Cited by 524
Ju, Y. S., Lee, W.-C., Shin, J.-Y., Lee, S., Bleazard, T., Won, J.-K., Kim, Y. T., Kim, J.-I., Kang, J.-H., & Seo, J.-S. (2012) · Genome Research · doi:10.1101/gr.133645.111 · Cited by 484
Oncogenes in solid human tumours
Pulciani, S., Santos, E., Lauver, A. V., Long, L. K., Aaronson, S. A., & Barbacid, M. (1982) · Nature · doi:10.1038/300539a0 · Cited by 478
Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase Fusions
Lovly, C. M., Gupta, A., Lipson, D., Otto, G., Brennan, T., Chung, C. T., Borinstein, S. C., Ross, J. S., Stephens, P. J., Miller, V. A., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0377 · Cited by 455
Ross, J. S., Wang, K., Gay, L., Al-Rohil, R., Rand, J. V., Jones, D. M., Lee, H. J., Sheehan, C. E., Otto, G. A., Palmer, G., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0352 · Cited by 454
Congenital Mesoblastic Nephroma t(12;15) Is Associated withETV6-NTRK3 Gene Fusion
Rubin, B. P., Chen, C.-J., Morgan, T. W., Xiao, S., Grier, H. E., Kozakewich, H. P., Perez-Atayde, A. R., & Fletcher, J. A. (1998) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65732-x · Cited by 437
Levis, M., Ravandi, F., Wang, E. S., Baer, M. R., Perl, A., Coutre, S., Erba, H., Stuart, R. K., Baccarani, M., Cripe, L. D., et al. (2011) · Blood · doi:10.1182/blood-2010-08-301796 · Cited by 398
Bourgeois, J. M., Knezevich, S. R., Mathers, J. A., & Sorensen, P. H. B. (2000) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200007000-00005 · Cited by 338
Longo, F. M., & Massa, S. M. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4024 · Cited by 298
Holgado-Madruga, M., Moscatello, D. K., Emlet, D. R., Dieterich, R., & Wong, A. J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.23.12419 · Cited by 277
Crizotinib in Anaplastic Large-Cell Lymphoma
Gambacorti-Passerini, C., Messa, C., & Pogliani, E. M. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1013224 · Cited by 276
ETV6‐NTRK3 is a common chromosomal rearrangement in radiation‐associated thyroid cancer
Leeman‐Neill, R. J., Kelly, L. M., Liu, P., Brenner, A. V., Little, M. P., Bogdanova, T. I., Evdokimova, V. N., Hatch, M., Zurnadzy, L. Y., Nikiforova, M. N., et al. (2014) · Cancer · doi:10.1002/cncr.28484 · Cited by 257
Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers
Ricarte-Filho, J. C., Li, S., Garcia-Rendueles, M. E. R., Montero-Conde, C., Voza, F., Knauf, J. A., Heguy, A., Viale, A., Bogdanova, T., Thomas, G. A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69766 · Cited by 241
Identification and Characterization of Novel Substrates of Trk Receptors in Developing Neurons
Qian, X., Riccio, A., Zhang, Y., & Ginty, D. D. (1998) · Neuron · doi:10.1016/s0896-6273(00)80620-0 · Cited by 238
Tomasson, M. H., Xiang, Z., Walgren, R., Zhao, Y., Kasai, Y., Miner, T., Ries, R. E., Lubman, O., Fremont, D. H., McLellan, M. D., et al. (2008) · Blood · doi:10.1182/blood-2007-09-113027 · Cited by 227
Tacconelli, A., Farina, A. R., Cappabianca, L., DeSantis, G., Tessitore, A., Vetuschi, A., Sferra, R., Rucci, N., Argenti, B., Screpanti, I., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.011 · Cited by 208
Rearrangements of NTRK1 gene in papillary thyroid carcinoma
Greco, A., Miranda, C., & Pierotti, M. A. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.10.009 · Cited by 190
Mechanisms of disease in hereditary sensory and autonomic neuropathies
Rotthier, A., Baets, J., Timmerman, V., & Janssens, K. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.227 · Cited by 168
Ardini, E., Bosotti, R., Borgia, A. L., Ponti, C. D., Somaschini, A., Cammarota, R., Amboldi, N., Raddrizzani, L., Milani, A., Magnaghi, P., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.06.001 · Cited by 166
Bishop, J. A., Yonescu, R., Batista, D., Begum, S., Eisele, D. W., & Westra, W. H. (2013) · Human Pathology · doi:10.1016/j.humpath.2013.03.017 · Cited by 162
Tognon, C. E., Garnett, M. J., Kenward, E., Kay, R., Morrison, K. B., & Sorensen, P. H. B. (2001) · PubMed · Cited by 154
Loeb, D. M., Stephens, R. M., Copeland, T. D., Kaplan, D. R., & Greene, L. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37053-9 · Cited by 132
TrkA Immunoglobulin-Like Ligand Binding Domains Inhibit Spontaneous Activation of the Receptor
Arévalo, J. C., Conde, B., Hempstead, B. L., Chao, M. V., Martín-Zanca, D., & Pérez, P. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.16.5908-5916.2000 · Cited by 122
Reuther, G. W., Lambert, Q. T., Caligiuri, M. A., & Der, C. J. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.23.8655-8666.2000 · Cited by 120
Aisner, D. L., Nguyen, T. T., Paskulin, D. D., Le, A. T., Haney, J., Schulte, N., Chionh, F. J. M., Hardingham, J. E., Mariadason, J. M., Tebbutt, N. C., et al. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0479-t · Cited by 119
Self-citationThe TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium
Russell, J. P., Powell, D. J., Cunnane, M. F., Greco, A., Portella, G., Santoro, M. M., Fusco, A., & Rothstein, J. L. (2000) · Oncogene · doi:10.1038/sj.onc.1203922 · Cited by 111
The neurotrophic receptor TrkB: a drug target in anti-cancer therapy?
Desmet, C. J., & Peeper, D. S. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5490-8 · Cited by 106
Minturn, J. E., Evans, A. E., Villablanca, J. G., Yanik, G. A., Park, J. R., Shusterman, S., Groshen, S. G., Hellriegel, E. T., Bensen-Kennedy, D. M., Matthay, K. K., et al. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1581-4 · Cited by 105
Ashcroft, M. A., Stephens, R. M., Hallberg, B., Downward, J., & Kaplan, D. R. (1999) · Oncogene · doi:10.1038/sj.onc.1202814 · Cited by 103
NTRK1 Fusion in Glioblastoma Multiforme
Kim, J., Lee, Y., Cho, H., Lee, Y., An, J., Cho, G.-H., Ko, Y. H., Joo, K. M., & Nam, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091940 · Cited by 101
Role of Neurotrophins in Neuropathic Pain
Siniscalco, D., Giordano, C., Rossi, F., Maione, S., & de Novellis, V. (2011) · Current Neuropharmacology · doi:10.2174/157015911798376208 · Cited by 100
Characterization of a newly identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia
Kralik, J. M., Kranewitter, W. J., Bösmüller, H. C., Marschon, R., Tschurtschenthaler, G., Rumpold, H. F., Wiesinger, K., Erdel, M., Petzer, A. L., & Webersinke, G. (2011) · Diagnostic Pathology · doi:10.1186/1746-1596-6-19 · Cited by 98
Identification of a Recurrent STRN/ALK Fusion in Thyroid Carcinomas
Pérot, G., Soubeyran, I., Ribeiro, A., Bonhomme, B., Savagner, F., Boutet-Bouzamondo, N., Hostein, I., Bonichon, F., Godbert, Y., & Chibon, F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087170 · Cited by 94
Coulier, F., Kumar, R., Ernst, M. K., Klein, R., Martín-Zanca, D., & Barbacid, M. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.8.4202-4210.1990 · Cited by 81
Morrison, K. B., Tognon, C. E., Garnett, M. J., Deal, C., & Sorensen, P. H. B. (2002) · Oncogene · doi:10.1038/sj.onc.1205669 · Cited by 81
Marchetti, A., Felicioni, L., Pelosi, G., Grammastro, M. D., Fumagalli, C., Sciarrotta, M., Malatesta, S., Chella, A., Barassi, F., Mucilli, F., et al. (2008) · Human Mutation · doi:10.1002/humu.20707 · Cited by 80
Weeraratna, A. T., Dalrymple, S. L., Lamb, J. C., Denmeade, S. R., Miknyoczki, S. J., Dionne, C. A., & Isaacs, J. T. (2001) · PubMed · Cited by 77
Ablation of TrkA function in the immune system causes B cell abnormalities
Coppola, V., Barrick, C. A., Southon, E. A., Celeste, A., Wang, K., Chen, B., Haddad, E., Yin, J. L., Nussenzweig, A., Subramaniam, A., et al. (2004) · Development · doi:10.1242/dev.01383 · Cited by 77
Role and Relevance of TrkB Mutations and Expression in Non–Small Cell Lung Cancer
Harada, T., Yatabe, Y., Takeshita, M., Koga, T., Yano, T., Wang, Y., & Giaccone, G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3034 · Cited by 61
Functional Characterization of Human Cancer-Derived TRKB Mutations
Geiger, T. R., Song, J., Rosado, A., & Peeper, D. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016871 · Cited by 58
A novel mutation within the extracellular domain of TrkA causes constitutive receptor activation
Arévalo, J. C., Conde, B., Hempstead, B. L., Chao, M. V., Martı́n-Zanca, D., & Pérez, P. (2001) · Oncogene · doi:10.1038/sj.onc.1204215 · Cited by 55
Tacconelli, A., Farina, A. R., Cappabianca, L. A., Gulino, A., & Mackay, A. R. (2005) · Future Oncology · doi:10.2217/14796694.1.5.689 · Cited by 53
Phosphotyrosine Residues in the Nerve‐Growth‐Factor Receptor (Trk‐A)
Baxter, R. M., Cohen, P., Obermeier, A., Ullrich, A., Downes, C. P., & Doza, Y. N. (1995) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1995.084_c.x · Cited by 51
IRS-1 and IRS-2 are recruited by TrkA receptor and oncogenic TRK-T1
Miranda, C., Greco, A., Miele, C., Pierotti, M. A., & OBBERGHEN, E. V. (2000) · Journal of Cellular Physiology · doi:10.1002/1097-4652(200101)186:1<35::aid-jcp1003>3.0.co;2-x · Cited by 50
Weiss, G. J., Hidalgo, M. M., Borad, M. J., Laheru, D. A., Tibes, R., Ramanathan, R. K., Blaydorn, L., Jameson, G., Jimeno, A., Isaacs, J. D., et al. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9774-6 · Cited by 47
Ranzi, V., Meakin, S. O., Miranda, C., Mondellini, P., Pierotti, M. A., & Greco, A. (2003) · Endocrinology · doi:10.1210/en.2002-221002 · Cited by 40
de Braud, F., Pilla, L., Niger, M., Damian, S., Bardazza, B., Martinetti, A., Pelosi, G., Marrapese, G., Palmeri, L., Cerea, G., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.2502 · Cited by 32
Richardson, C. A., & Leitch, B. (2004) · The Journal of Comparative Neurology · doi:10.1002/cne.20386 · Cited by 31
Biological activity of the thyroid TRK-T3 oncogene requires signalling through Shc
Roccato, E., Miranda, C., Ranzi, V., Gishizki, M., Pierotti, M. A., & Greco, A. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600544 · Cited by 30
Functional characterization of NTRK1 mutations identified in melanoma
Miranda, C., Mazzoni, M., Sensi, M., Pierotti, M. A., & Greco, A. (2014) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22200 · Cited by 27
Role of STAT3 in In Vitro Transformation Triggered by TRK Oncogenes
Miranda, C., Fumagalli, T., Anania, M. C., Vizioli, M. G., Pagliardini, S., Pierotti, M. A., & Greco, A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009446 · Cited by 26
Expression of TRK-T1 oncogene induces differentiation of PC12 cells.
Greco, A., Orlandi, R., Mariani, C., Miranda, C., Mg, B., Cattaneo, A., Pagliardini, S., & Pierotti, M. A. (1993) · PubMed · Cited by 19
An in vivo functional genetic screen reveals a role for the TRK-T3 oncogene in tumor progression
Edel, M. J., Shvarts, A., Medema, J. P., & Bernards, R. (2004) · Oncogene · doi:10.1038/sj.onc.1207667 · Cited by 10
Cited by
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Self-citationDoebele, R. C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A. T., Farago, A. F., Blakely, C. M., Seto, T., Cho, B. C., Tosi, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30691-6 · Cited by 1,790
Self-citationNTRK fusion-positive cancers and TRK inhibitor therapy
Cocco, E., Scaltriti, M., & Drilon, A. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0113-0 · Cited by 1,485
Drilon, A., Siena, S., Ou, S.-H. I., Patel, M., Ahn, M. J., Lee, J., Bauer, T. M., Farago, A. F., Wheler, J. J., Liu, S. V., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1237 · Cited by 826
Self-citationNTRK gene fusions as novel targets of cancer therapy across multiple tumour types
Amatu, A., Sartore-Bianchi, A., & Siena, S. (2016) · ESMO Open · doi:10.1136/esmoopen-2015-000023 · Cited by 601
Metadata
- Authors
- Vaishnavi, A., Le, A. T., & Doebele, R. C.
- Venue
- Cancer Discovery
- Published
- 2015-01-01
- Volume
- 5
- Issue
- 1
- Pages
- 25-34
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2109269285
- Cited by
- 642
- References
- 89
- FWCI
- 16.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.